Primary Prevention of Heart Failure
نویسندگان
چکیده
منابع مشابه
Primary Prevention of Heart Failure
Most heart failure research and quality improvement efforts are targeted at treatment and secondary prevention of patients with manifest heart failure. This is distinct from coronary disease where primary prevention has been a focus for over three decades. Given the current importance and the projected worsening of heart failure epidemiology, a more focused effort on prevention is urgently needed.
متن کاملPrimary Prevention of Heart Failure in Older Adults.
H eart failure is increasing in frequency and is associated with substantial morbidity and mortality. The incidence of heart failure is highest among older adults (1,2). Treatment of heart failure, a leading cause of hospitalization for people older than 65 years of age, costs more than $30 billion per year in the United States (3,4). It follows that identifying modifiable risk factors for prim...
متن کاملPrimary prevention of stroke: blood pressure, lipids, and heart failure.
Stroke contributes significantly to morbidity, mortality, and disability worldwide. Despite the successes accomplished in the acute treatment and rehabilitation of stroke, the global burden of this disease can only be tackled with co-ordinated approaches for primary prevention. Stroke is a heterogeneous disease and the contribution of individual risk factors to its occurrence estimated by popul...
متن کاملPrevention of Heart Failure.
In light of the increasing prevalence, morbidity, and mortality of heart failure, preventative strategies are urgently needed. Risk factors include coronary artery disease, renal insufficiency, diabetes, and smoking. Essential strategies for prevention of heart failure are modification of risk factors for its development, and detection and treatment of asymptomatic left ventricular dysfunction ...
متن کاملEmpagliflozin and the Prevention of Heart€Failure
SEE PAGE 347 H eart failure develops in more than 1 in 5 patients with diabetes mellitus (DM) older than 65 years of age and augers an extremely poor prognosis, with a median survival of approximately 4 years. The landmark EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) showed that empagliflozin significantly reduced the primary composite...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ISRN Cardiology
سال: 2012
ISSN: 2090-5599
DOI: 10.5402/2012/982417